IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 297 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 1.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,732,000 | -13.2% | 389,588 | 0.0% | 0.66% | -33.3% |
| Q2 2022 | $4,301,000 | -33.7% | 389,588 | 0.0% | 0.98% | -35.9% |
| Q1 2022 | $6,487,000 | -12.8% | 389,588 | 0.0% | 1.53% | -37.4% |
| Q4 2021 | $7,437,000 | -22.6% | 389,588 | 0.0% | 2.45% | -29.8% |
| Q3 2021 | $9,607,000 | -27.0% | 389,588 | -23.0% | 3.49% | -35.4% |
| Q2 2021 | $13,163,000 | -26.5% | 505,890 | -10.6% | 5.41% | -28.3% |
| Q1 2021 | $17,916,000 | -31.8% | 565,890 | 0.0% | 7.55% | -19.6% |
| Q4 2020 | $26,257,000 | +33.6% | 565,890 | -5.2% | 9.39% | +12.8% |
| Q3 2020 | $19,650,000 | +18.5% | 596,890 | -1.2% | 8.32% | +12.6% |
| Q2 2020 | $16,577,000 | +12.7% | 603,890 | +22.9% | 7.39% | -17.1% |
| Q1 2020 | $14,710,000 | +17.1% | 491,390 | +8.3% | 8.92% | +17.2% |
| Q4 2019 | $12,564,000 | – | 453,890 | – | 7.62% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |